A non-sedative, antihistamine syrup Histaban (loratadine) has been launched in Sri Lanka by GlaxoSmithKline Pharmaceuticals (GSK) as a prescription medication for allergic conditions. The syrup intended for paediatric use, is manufactured in Sri Lanka at the Glaxo Wellcome Ceylon plant, which has been in operation for more than 50 years, the company said in a [...]

The Sundaytimes Sri Lanka

GSK launches locally developed antihistamine ‘Histaban’

View(s):

A non-sedative, antihistamine syrup Histaban (loratadine) has been launched in Sri Lanka by GlaxoSmithKline Pharmaceuticals (GSK) as a prescription medication for allergic conditions.

The syrup intended for paediatric use, is manufactured in Sri Lanka at the Glaxo Wellcome Ceylon plant, which has been in operation for more than 50 years, the company said in a statement this week.

“Loratadine is a second-generation antihistamine, and the availability of a locally developed product from GSK will be welcomed by the medical fraternity,” said Stuart Chapman, Managing Director of GSK Pharmaceuticals in Sri Lanka. “GSK’s highest global standards have been adhered to in the manufacture, to ensure quality, safety and efficacy.”

Because Histaban is a long-acting antihistamine, a single daily dose is recommended. There is no restriction in a patient’s activities since it is non-sedative. The syrup is retailed in a 60ml glass bottle.




Share This Post

DeliciousDiggGoogleStumbleuponRedditTechnoratiYahooBloggerMyspace
comments powered by Disqus

Advertising Rates

Please contact the advertising office on 011 - 2479521 for the advertising rates.